Kyverna Therapeutics, Inc.
KYTX · Biological Products, (No Disgnostic Substances)
Latest available SEC filing: 4 ·
Latest disclosures
-
Latest financial period: Q2 2026
Financial facts · Filed
-
Clark Ian T: Form 4
Insider disclosure · Filed · Report period 27 May 2026
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
Institutional holders by security
Choose a share class to see reported 13F positions and quarterly changes. Different securities have separate holder histories.
- KYTX · 501976104 - Common Stock, par value $0.00001 per share
Company details and SEC sources
CIK 0001994702 · SEC filing index. Filing dates describe disclosures, not live market data.
- Listed symbols
- KYTX on Nasdaq
- SEC industry group
- Biological Products, (No Disgnostic Substances) (Office of Life Sciences)
- Business address
- 5980 Horton Street, Suite 200, Emeryville, CA
- Incorporated in
- DE
- Fiscal year end
- 31 December
At a glance
Names, identifiers, and filing context for this profile.
2 identity fields